Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing orally bioavailable molecular glue degraders that selectively induce degradation of disease-causing proteins. The company applies its QuEEN discovery engine, combining targeted protein degradation, chemistry, structural biology, proteomics, and computational methods, to pursue previously undruggable targets across immunology, inflammation, oncology, and other serious diseases. Its lead partnered program, MRT-6160, is a VAV1-directed molecular glue degrader for immune-mediated diseases and is licensed globally to Novartis. Monte Rosa is also advancing MRT-8102, a NEK7-directed degrader for IL-1beta/NLRP3-driven inflammatory disease, and MRT-2359, a GSPT1-directed degrader for MYC-driven solid tumors. The company additionally maintains earlier-stage discovery programs including degraders targeting CDK2 and Cyclin E1.